BMY

Bristol-Myers Squibb remains a high-quality large-cap biopharma anchored by durable oncology and cardiovascular franchises, with 2025 revenue of $48.2B led by Eliquis ($14.4B) and Opdivo ($10.0B). The business model is sustainable only if BMY consistently replenishes its portfolio, because large products face lifecycle and competition pressures. Pipeline productivity is being reinforced through partnerships (e.g., BioNTech’s BNT327) that can broaden exposure to fast-growing solid-tumor modalities.

Financially, BMY is highly cash-generative: the company reported 2025 cash provided by operations of $14.2B and ended 2025 with $11.1B of cash, cash equivalents, and marketable debt securities. In Q1 2026, non-GAAP EPS was $1.58, and management reaffirmed 2026 guidance for revenue of ~$46.0B–$47.5B and non-GAAP EPS of $6.05–$6.35, trending toward the upper end. The 4.31% dividend yield is attractive, but the market’s muted multiple reflects near-term top-line pressure and patent/loss-of-exclusivity risk.

Over the next 12 months, the key debate is whether execution and launches can offset erosion while protecting the earnings power implied by 2026 guidance. Catalysts include the July 30, 2026 Q2 print, evidence of continued Eliquis growth (BMY guided +10% to +15% worldwide in 2026), and incremental pipeline readouts/business development. Risks center on faster-than-expected competitive dynamics and any guidance de-risking if erosion accelerates.

Recommendation: HOLD. The dividend and reaffirmed 2026 outlook support downside protection, but visibility past the upcoming patent/competition wave remains the swing factor for multiple expansion.